Time-to-progression (TTP) following frontline R-CHOP is a surprisingly reliable indicator of how well patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) will respond to further treatment, according to new research. It’s the kind of finding that makes oncologists perk up – a simple metric that could really impact patient care.
The study, published in Therapeutic Advances in Medical Oncology1, is particularly noteworthy because it’s based on real-world data, offering a practical way to predict prognosis.
Approximately two-thirds of patients with DLBCL achieve a cure with initial treatment involving anthracycline-based chemoimmunotherapy, such as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone – commonly known as R-CHOP. However, the authors explained that 30-40% of patients either don’t respond to R-CHOP initially or experience a relapse after achieving a complete response.
Subsequent treatments tend to be ineffective, they added.2 While platinum-based salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is typical, many patients aren’t eligible for ASCT, and even those who are may relapse.
Newer therapies, like CAR T-cell therapies and monoclonal antibodies, offer potential cures, but they’re often expensive and complex to administer. This underscores the need to identify which patients will truly benefit from these advanced – and often limited – resources.
To address this, researchers analyzed real-world data to pinpoint factors linked to survival and treatment response following R-CHOP.
They reviewed data from 231 patients with R/R DLBCL treated at a tertiary medical center. Of these, 88 (38.1%) were primarily resistant to R-CHOP, while 143 (61.9%) experienced a recurrence. Stratifying patients by TTP revealed a significant difference in two-year overall survival (OS): 35.4% for those with TTPs under 12 months, compared to 74.4% for those with TTPs exceeding 24 months. Patients with shorter TTPs also showed lower response rates to second-line therapies and were less likely to undergo ASCT. Importantly, TTP emerged as an independent prognostic factor for both OS and progression-free survival (PFS) in a multivariate analysis.
To validate these findings, the investigators also analyzed data from Taiwan’s National Health Insurance Research Database, encompassing 723 patients with R/R DLBCL, and confirmed the initial results.
These findings echo previous research consistently demonstrating a strong link between the timing of relapse or refractoriness and long-term survival outcomes.
“Our study found that, aside from being linked to poor survival outcomes, a short TTP is significantly associated with lower response rates to second-line treatment and a decreased likelihood of proceeding to ASCT,” the authors wrote.
This highlights the “urgent need” for more innovative treatments for these patients.
Beyond TTP, the multivariate analysis identified several other factors associated with poor overall survival: bulky lesions at diagnosis, low serum albumin before salvage therapy, and high International Prognostic Index scores. Poor progression-free survival was linked to male gender and low hemoglobin levels prior to salvage therapy.
The study’s retrospective nature and resulting missing data represent a limitation, the investigators acknowledged. However, they emphasized that the validation cohort strengthens the robustness of their findings, and further studies with standardized cutoff values would refine the prognostic stratification.
- A short time-to-progression (TTP) after initial R-CHOP treatment is a strong predictor of poor outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma.
- Patients with a TTP of less than 12 months had significantly lower overall survival rates compared to those with a TTP longer than 24 months.
- The study validates the importance of TTP as a prognostic factor using both single-center and population-based data.
- Factors like bulky lesions, low albumin, and high International Prognostic Index scores also contribute to poor prognosis.
What does this mean for patients? Understanding a patient’s TTP after initial R-CHOP treatment can help doctors better predict their response to subsequent therapies and guide treatment decisions.
